ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,050 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 376-400 of 1,000 matching filings.

Per page
25
Current page
16
6-K File 001-11960

UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD

Filing date
06 Sep 2023
Reporting date
06 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Sep 2023
Reporting date
01 Sep 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
16 Aug 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Aug 2023
Reporting date
01 Aug 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER

Filing date
28 Jul 2023
Reporting date
28 Jul 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION

Filing date
17 Jul 2023
Reporting date
17 Jul 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Jul 2023
Reporting date
03 Jul 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER

Filing date
03 Jul 2023
Reporting date
03 Jul 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

ANNUAL REPORT

Filing date
28 Jun 2023
Reporting date
31 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION

Filing date
09 Jun 2023
Reporting date
09 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS

Filing date
09 Jun 2023
Reporting date
09 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS

Filing date
02 Jun 2023
Reporting date
02 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
01 Jun 2023
Reporting date
01 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jun 2023
Reporting date
01 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER

Filing date
01 Jun 2023
Reporting date
01 Jun 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER

Filing date
26 May 2023
Reporting date
26 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
25-NSE File 001-11960

25-NSE filing

Filing date
25 May 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTORATE CHANGE

Filing date
22 May 2023
Reporting date
22 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER

Filing date
17 May 2023
Reporting date
17 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 May 2023
Reporting date
09 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FARXIGA EXTENDED IN THE US FOR HEART FAILURE

Filing date
09 May 2023
Reporting date
09 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 May 2023
Reporting date
02 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER

Filing date
02 May 2023
Reporting date
02 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
02 May 2023
Reporting date
02 May 2023
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .